Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Prospective Study Evaluating the Role of Daratumumab in HLA Desensitization Prior to Transplantation

NCT05300451 is registered in ClinicalTrials.gov with Barry A. Boilson as lead sponsor.

NCT NCT05300451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05300451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Prospective Study Evaluating the Role of Daratumumab in HLA Desensitization Prior to Transplantation
Lead sponsor
Barry A. Boilson
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
March 31, 2022
Completion date
December 31, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiac transplant